Last reviewed · How we verify
AV-001
AV-001 is a small molecule that targets the PI3K pathway to modulate immune responses.
AV-001 is a small molecule that targets the PI3K pathway to modulate immune responses. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | AV-001 |
|---|---|
| Sponsor | Vasomune Therapeutics, Inc. |
| Drug class | PI3K inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AV-001 works by inhibiting the PI3K delta subunit, which is involved in the activation of immune cells. This inhibition leads to a reduction in inflammation and an enhancement of anti-tumor immune responses. By modulating the PI3K pathway, AV-001 aims to improve the efficacy of cancer immunotherapies.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
Key clinical trials
- Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia. (PHASE2)
- Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury. (PHASE2)
- A First-in-Human Study of AV-001 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AV-001 CI brief — competitive landscape report
- AV-001 updates RSS · CI watch RSS
- Vasomune Therapeutics, Inc. portfolio CI